<DOC>
	<DOCNO>NCT00563056</DOCNO>
	<brief_summary>Flutiform® compare individual component Flixotide® ( Fluticasone ) Foradil® ( Formoterol ) adolescent adult patient .</brief_summary>
	<brief_title>An Open , Randomised , Parallel Group Multicentre Study Compare Efficacy Safety Flutiform® pMDI v Fluticasone pMDI Plus Formoterol DPI Adolescent Adult Subjects With Mild Moderate-severe Persistent , Reversible Asthma</brief_title>
	<detailed_description>This study involve 12 week treatment phase . During treatment phase subject receive Flutiform® Flixotiole® Foradil® individual componements . Efficacy assess lung function test asthma symptom , sleep disturbance . Safety assess adverse event , vital sign , lab test ECGs .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female subject least 12 year old ( female less one year postmenopausal must negative serum urine pregnancy test record screen visit prior first dose study medication , nonlactating , willing use adequate highly effective method contraception throughout study sexually active . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilization , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device , hormonal ) , sexual abstinence vasectomise partner ) . 2 . Known history mild moderatesevere persistent , reversible asthma ≥ 6 month prior screen visit . 3 . Demonstrate FEV1 ≥40 % ≤85 % predict normal value ( Quanjer et al , 19931 ) screen phase follow appropriate withhold asthma medication ( applicable ) . No β2agonist use day screen . No use inhale combination asthma therapy day screen . Inhaled corticosteroid allow day screen . 4 . Documented reversibility ≥15 % FEV1 screening phase . 5 . Demonstrate satisfactory technique use study medication . 6 . Willing able enter information diary attend study visit . 7 . Willing able substitute study medication pre study prescribe asthma medication duration study . 8 . Written inform consent obtain Exclusion criterion : 1 . Near fatal lifethreatening ( include intubation ) asthma within past year . 2 . Hospitalization emergency visit asthma within past year . 3 . History systemic ( oral parenteral ) corticosteroid medication within 1 month Screening Visit . 4 . History omalizumab use within past 6 month . 5 . History leukotriene receptor antagonist use , e.g . montelukast , theophylline within past week . 6 . Current evidence history clinically significant disease abnormality include uncontrolled coronary artery disease , congestive heart failure , myocardial infarction , cardiac dysrhythmia . 'Clinically significant ' defined disease , opinion Investigator , would put patient risk study participation , would affect outcome study . 7 . In investigator opinion clinically significant upper low respiratory infection within 4 week prior Screening Visit . 8 . Significant , nonreversible , active pulmonary disease ( e.g. , chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , bronchiectasis , tuberculosis ) . 9 . Known Human Immunodeficiency Virus ( HIV ) positive status . 10 . A smoke history equivalent `` 10 pack year '' ( i.e. , least 1 pack 20 cigarette /day 10 year 10 packs/day 1 year , etc. ) . 11 . Current smoke history within 12 month prior Screening Visit . 12 . Current evidence history alcohol and/or substance abuse within 12 month prior Screening Visit . 13 . Subjects take Bblocking agent , tricyclic antidepressant , monoamine oxidase inhibitor , astemizole ( Hismanal ) , quinidine type antiarrhythmic , potent CYP 3A4 inhibitor ketoconazole within past week . 14 . Current use medication effect bronchospasm and/or pulmonary function . 15 . Current evidence history hypersensitivity idiosyncratic reaction test medication component . 16 . Receipt investigational drug within 30 day Screening Visit ( 12 week oral injectable steroid ) . 17 . Current participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Formoterol</keyword>
	<keyword>Fluticasone</keyword>
	<keyword>Asthma</keyword>
</DOC>